YocoBio

YocoBio is a Swiss biotechnology company developing a novel platform for the oral delivery of biologics, specifically targeting gastrointestinal disorders. As a spin-off from the University of Basel's Biozentrum, the company utilizes engineered yeast (Saccharomyces cerevisiae) to produce and release therapeutic proteins directly within the gut lumen. This localized delivery mechanism is designed to treat Inflammatory Bowel Disease (IBD) by concentrating the drug at the site of inflammation while reducing systemic exposure and associated side effects. YocoBio's technology aims to transform the treatment landscape for chronic gut conditions by replacing traditional injections with a more patient-friendly oral format. The company is led by experienced entrepreneurs who previously founded T3 Pharmaceuticals.